Healthcare / Medical Instruments & SuppliesNYSE American
$1.94
-0.04 (-2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.5M · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$190M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-115.6%
↓Gross Margin
52.7%
↑Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-2.8%
FCF CAGR
—
FCF margin
-42.6%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.4M · net income $-21.6M · FCF $-13.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $32.4M | $32.4M | $26.9M | $26.8M | $28.1M | $35.0M | $26.6M | $28.9M | $29.3M | $31.1M | $32.2M | $37.7M | $35.0M | $38.0M | $46.6M | $42.0M | $54.1M | $51.1M |
| Net Income | $-21.6M | $-21.6M | $-24.0M | $-20.7M | $-18.3M | $-10.7M | $-6.6M | $-4.6M | $116756.00 | $-5.9M | $-5.3M | $-7.4M | $-5.2M | $-68.8M | $-9.2M | $-32.0M | $-19.9M | $-27.5M |
| EBITDA | $-20.6M | $-20.6M | $-23.8M | $-21.2M | $-18.3M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.25 | -0.25 | -0.30 | -0.27 | -0.26 | -0.16 | -0.11 | -0.10 | -0.03 | -0.32 | -0.54 | -0.35 | -0.26 | -5.95 | -1.33 | -5.84 | -3.59 | — |
| Gross Margin | 52.7% | 52.7% | 54.2% | 55.5% | 65.6% | 66.3% | 71.2% | 78.8% | 80.5% | 65.5% | 76.6% | 72.3% | 76.5% | 71.1% | 68.3% | 70.2% | 71.2% | 66.7% |
| Operating Margin | -68.3% | -68.3% | -91.9% | -81.6% | -66.7% | -36.8% | -25.2% | -16.7% | -8.4% | -19.0% | -20.0% | -14.4% | -15.4% | -23.2% | -22.8% | -76.1% | -35.1% | -46.6% |
| Net Margin | -66.8% | -66.8% | -89.3% | -77.4% | -65.0% | -30.6% | -25.0% | -15.9% | 0.4% | -18.9% | -16.4% | -19.5% | -14.9% | -180.8% | -19.8% | -76.3% | -36.9% | -53.8% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.29 | 0.29 | 0.53 | 0.25 | 0.18 | — | 0.03 | — | — | — | — | -1.03 | -1.47 | -1.58 | -0.90 | -0.92 | 0.76 | — |
| Current Ratio | 1.56 | 1.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-13.8M | $-13.8M | $-8.5M | $-9.5M | $-10.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -115.6% | -115.6% | -210.3% | -94.5% | -57.3% | -31.7% | -19.2% | -20.2% | 8.9% | 22.2% | 24.6% | 41.7% | 41.5% | 587.6% | 49.2% | 170.1% | -190.2% | -359.8% |
| Valuation | ||||||||||||||||||
| P/B | 9.43 | 9.43 | 17.66 | 6.41 | 5.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 20.3% | 20.3% | 0.5% | -4.9% | — | 31.5% | -7.9% | -1.5% | -5.8% | -3.2% | -14.6% | 7.6% | -7.9% | -18.3% | 10.9% | -22.3% | 5.7% | — |
| EPS Growth | 16.7% | 16.7% | -11.1% | -3.8% | — | -45.5% | -10.0% | -233.3% | 90.6% | 40.7% | -54.3% | -34.6% | 95.6% | -347.4% | 77.2% | -62.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.30 → -0.25
Residual
-8.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.